Results 41 to 50 of about 5,946,067 (288)

Incidence and Risk Factors of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients Having Undergone Autologous Stem Cell Transplantation [PDF]

, 2012
Background: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a severe complication of bisphosphonate therapy. Due to their long survival and subsequently high cumulative doses of bisphosphonates, multiple myeloma patients have the highest risk ...
Baumann, Philipp, Bumeder, Irmgard, Hörauf, Natalie, Oduncu, Fuat S., Otto, Sven, Pautke, Christoph, Röhnisch, Tim, Schmidmaier, Ralf, Then, Cornelia, Tresckow, Emmo von   +9 more
core   +1 more source

Role of Zoledronic Acid Supplementation in Reducing Post-Surgical Recurrence of Giant Cell Tumor of Bone: A Meta-Analysis of Comparative Studies

Cureus, 2021
Zoledronic acid is a bisphosphonate that has recently gained interest in adjuvant therapy for giant cell tumor of bone (GCTB). It has an apoptotic effect on osteoclasts that are precursors of GCTB.
Arvind Kumar, S. Sinha, Yawar Haider, Javed Jameel, Sandeep Kumar   +4 more
semanticscholar   +1 more source

Zoledronic acid inhibits the bone metastasis of breast cancer by repressing exosome-loaded DKK1

Bangladesh Journal of Pharmacology, 2022
This study is designed to investigate the mechanism underlying zoledronic acid for the bone metastasis of breast cancer. Dickkopf 1 (DKK1) was both expressed in breast cancer cells and exosomes isolated from breast cancer cells.
Bin Bin Song, Mao Yi Xu, Xiao Fang Xu, Xia Li, Ming Chen   +4 more
doaj   +1 more source

Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents [PDF]

, 2014
Bone metastases in advanced cancer frequently cause painful complications that impair patient physical activity and negatively affect quality of life. Pain is often underreported and poorly managed in these patients.
A Kretzschmar, A Mañas, A Wardley, AT Stopeck, C Langer, C Logothetis, Charles S. Cleeland, CI Ripamonti, CJ Logothetis, CS Cleeland, CS Cleeland, D Henry, D Patrick, DH Henry, DL Patrick, Donald L. Patrick, DS Ernst, E Basch, E Chow, F Saad, F Saad, G Apolone, G Cartenì, G Storto, GN Hortobagyi, GN Hortobagyi, HI Scher, JJ Body, JJ Body, K Altundag, K Fizazi, K Harris, Katarina Öhrling, KC Chung, KP Weinfurt, KP Weinfurt, L Atahan, L Costa, L Fallowfield, Lesley Fallowfield, LS Matza, LS Rosen, LS Rosen, LS Rosen, M Huisman, M Martin, M Tomblyn, MG Lam, MJ Fisch, N Kohno, N Takeda, P Hoskin, P Hoskin, R Moos von, R Moos von, Rachel Wei, RE Coleman, RE Coleman, RE Coleman, RH Dworkin, RL Theriault, Roger von Moos, S Deandrea, S Nilsson, S Vadhan-Raj, SD Mathias, T Kijima, V Vassiliou, V Vassiliou, Yi Qian   +69 more
core   +1 more source

Retrospective Study of the Effects of Zoledronic Acid on Muscle Mass in Osteoporosis Patients

Drug Design, Development and Therapy, 2021
Purpose Several osteoporosis drugs can continuously improve bone mass, but the impact on muscle mass is still unknown. This study aims to investigate how zoledronic acid monotherapy affected muscle mass in osteoporosis patients.
Chun-Feng Huang, M. Shiao, Tso-Yen Mao
semanticscholar   +1 more source

Local administration of zoledronic acid prevents traumatic osteonecrosis of the femoral head in rat model

Journal of Orthopaedic Translation, 2021
Background Osteonecrosis of the femoral head (ONFH) is a refractory disease due to its unclear pathomechanism. Neither conservative treatment nor surgical treatment during the early stage of ONFH achieves satisfactory results.
Jun Zhao, T. Yue, Shibi Lu, H. Meng, Qiu-Xia Lin, Haiyang Ma, Guang-Bo Liu, Huo Li, Qiang Lu, Ai-yuan Wang, Wen-jing Xu, Jing Feng, Yiqun Wan, Sida Liao, Xue-feng Zhou, Jiang Peng   +15 more
semanticscholar   +1 more source

Annual Zoledronic Acid for the Treatment of Osteoporosis: A Randomized Controlled Trial

Journal of Orthopedics, Traumatology and Rehabilitation, 2023
Context: Osteoporosis remains a significant public health problem in many parts of the world, including India. The efficacy of oral bisphosphonates is lower because of poor compliance.
Asif Hussain, Sushil Kumar Saini, Jaydeep Patel, Chandra Prakash Pal, Hemant Singh Chahar, Rohit Yadav   +5 more
doaj   +1 more source

Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis

Medicina Oral, 2020
Background The aim of the present study was to analyse the incidence, risk ratio (RR) and prognoses of two types of medication-related osteonecrosis of the jaws (MRONJ): denosumab-related osteonecrosis of the jaws (DRONJ) and Bisphosphonate-Related ...
Álvaro Limones, L. Sáez-Alcaide, S. Díaz-Parreño, A. Helm, M. Bornstein, P. Molinero-Mourelle   +5 more
semanticscholar   +1 more source

Medication-related osteonecrosis of the jaw: clinical and practical guidelines [PDF]

, 2016
Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse drug reaction, consisting of progressive bone destruction in the maxillofacial region of patients.
Allen, Bamias, Bedogni, Berenson, Brauner, Carlson, Coleman, Damm, Delmas, Delmas, Delmas, Dimopoulos, Fedele, Fizazi, Grbic, Guarneri, Hellstein, Hortobagyi, Kos, Lo, Marx, Mauri, Nussbaum, Papapoulos, Pompa, Qi, Qi, Reid, Ripamonti, Romeo, Rugani, Ruggiero, Ruggiero, Ruggiero, Saad, Saad, Scagliotti, Scoletta, Seth, Tenore, Vahtsevanos, Vandone, Yamazaki   +42 more
core   +2 more sources

Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis.

PLoS ONE, 2012
BackgroundZoledronic acid is widely used as adjuvant chemotherapy for the treatment of breast cancer. However, previous trials reported inconsistent findings regarding their clinical efficacy and safety.
Wei-Wei Huang, Cheng Huang, Jian Liu, Hong-Yu Zheng, Lin Lin   +4 more
doaj   +1 more source